Home Clinical trials For patients Ovary BGOG-ov56/DOVACC

BGOG-ov56/DOVACC

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients With Recurrent Ovarian Cancer

Open
Trial drug
UV1, Olaparib, Durvalumab
Grade
High grade, Low grade
Prior lines
1, 2, 3
Histology
Serous, Endometrioid Clear-cell Mucinous Other (bv. mixed/rare)
Platin
Platinum sensitive
Phase
II

Treatment

This study consists of three different treatment options: 

  • Olaparib
  • Olaparib + Durvalumab
  • Olaparib + Durvalumab + UV1

Olaparib is administered twice daily as a tablet. 
Durvalumab is administered intravenously once per month. 
UV1 is a vaccination, administered 4 times in the first 10 days and once per month in the subsequent 4 months.

To be eligible for this trial you cannot have an abnormality in your BRCA genes.
You will be randomly allocated to one of the treatment groups.

Treatment duration

The treatment with Olaparib can continue until disease progression, unacceptable toxicities or until you decide to stop.
The treatment with Durvalumab can continue for maximum 24 months. The treatment will be stopped earlier in case of disease progression, unacceptable toxicity or in case you decide to stop.
UV1 will only be administered in the first 5 months.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.